Investigational drug · Phase 2
ML-016
Also called: iNPG-pDox
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Solid Tumor With Lung and/or Liver Involvement.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ML-016"
First trial start
2026
Sep 25, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ML-016", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor With Lung and/or Liver Involvement
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ML-016" as an intervention, largest first.
BrYet US, Inc.Industry
NCT07723482 · 108 participants (planned) · Start Sep 25, 2026 · Primary completion Oct 2027
Drug: ML-016 · For: Advanced Solid Tumor With Lung and/or Liver Involvement
Sites: Miranda, Australia; Wollongong, Australia; Buderim, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Surface Engineering and Multimodal Imaging of Multistage Delivery Vectorsin Metastatic Breast Cancer.
Goel S, Ferrari M, Shen H · Bio Protoc 2021
- Sequential deconstruction of composite drug transport in metastatic breast cancer.
Goel S, Zhang G, Dogra P, et al. · Sci Adv 2020
- An injectable nanoparticle generator enhances delivery of cancer therapeutics.
Xu R, Zhang G, Mai J, et al. · Nat Biotechnol 2016
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.